Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
复制标题
DOI：
10.1073/pnas.97.19.10526
复制
发表时间：
2000-09-12
影响因子：
11.1
通讯作者：
Cerami, A
中科院分区：
文献类型：
--
作者：
Brines, ML;Ghezzi, P;Cerami, A
促红细胞生成素（EPO），公认其在红细胞生成中的核心作用，也介导神经保护时，重组形式（r-HuEPO）直接注射到缺血啮齿动物脑。我们观察到EPO受体在脑毛细血管中的丰富表达，这可能为循环EPO进入脑提供了途径。在证实这一假设，全身施用的r-Hu-EPO之前或长达6小时后，局灶性脑缺血损伤减少了约50- 75%。R-Hu-EPO还改善了脑震荡损伤的程度、实验性自身免疫性脑脊髓炎中的免疫损伤以及红藻氨酸盐的毒性。鉴于R-Hu-EPO的优异安全性，临床试验评估全身施用的R-HuEPO作为一般神经保护治疗是必要的。
Erythropoietin (EPO), recognized for its central role in erythropoiesis, also mediates neuroprotection when the recombinant form (r-HuEPO) is directly injected into ischemic rodent brain. We observed abundant expression of the EPO receptor at brain capillaries, which could provide a route for circulating EPO to enter the brain. In confirmation of this hypothesis, systemic administration of r-Hu-EPO before or up to 6 h after focal brain ischemia reduced injury by approximate to 50-75%. R-Hu-EPO also ameliorates the extent of concussive brain injury, the immune damage in experimental autoimmune encephalomyelitis, and the toxicity of kainate, Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-HuEPO as a general neuroprotective treatment are warranted.